? ? Sepsis is lethal, common, and expensive. The hospital case mortality rate for severe sepsis (sepsis plus organ dysfunction) is 30-50%; there are 751,000 cases of severe sepsis in the US annually at a cost of $17 billion. The endothelial response is emerging as a critical element of sepsis pathophysiology. Preclinical data and small human studies suggest that endothelial cells are responsible for increased leukocyte adhesion, inflammation, activation of coagulation, and respond to increased levels of the endothelial cell mediator Vascular Endothelial Cell Growth Factor (VEGF). Furthermore, the endothelium plays an active role in microcirculatory homeostasis and the preservation of microvascular flow. We propose to study the endothelium by performing a comprehensive endothelial cell """"""""read-out"""""""" through the measurement of circulating levels of endothelial cell biomarkers as well as direct visualization of microcirculatory flow with in-vivo videomicroscopy. Accordingly, the broad, long-term objective of this project is to study the role of the endothelium in sepsis in a large, heterogeneous group of patients. To accomplish this, we will investigate two specific aims: 1) to study biomarkers of endothelial cell activation in sepsis; and, 2) to study microcirculatory flow in sepsis. The overall hypotheses of this project is that severe sepsis is associated with endothelial dysfunction; that endothelial dysfunction, in turn, is predictive of subsequent organ failure and death; and that early effective protocol-directed resuscitation attenuates endothelial dysfunction leading to improved survival. To test this hypothesis, we will utilize patients, ancillary measurements (notably in-vivo assessment of microcirculatory flow), and additional samples and assays from the ProCESS clinical trial. ProCESS is a large, multicenter, randomized, controlled clinical trial testing the efficacy and mechanisms behind protocolized goal-directed resuscitation. To conduct this line of investigation directed at the endothelium and microcirculation that was not addressed in the original trial, we will select 8 ProCESS study sites for participation in this ancillary study. We will directly visualize and quantify the presence of disturbances in sublingual microcirculatory flow utilizing the novel bedside technique of orthogonal polarization microscopy. Furthermore, we will develop a multi-marker panel that assesses degree of endothelial cell dysfunction and subsequent mortality risk. We will also capitalize on the randomly assigned interventions in the ProCESS clinical trial to observe differences in endothelial response across the alternative resuscitation strategies. Improved understanding of these mechanisms may lead to strategies to predict outcome, to select patients for tailored (endothelium-directed) therapies, to follow treatment response, and to develop novel therapies for endothelial dysfunction in sepsis. ? ? The goal of this project is to study the endothelium in patients who are critically ill from an infection. The information gained from this project may lead to new methods to diagnose and treat this important patient population. (End of Abstract) ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL091757-01A1
Application #
7497803
Study Section
Special Emphasis Panel (ZHL1-CSR-H (F1))
Program Officer
Mcdonald, Cheryl
Project Start
2008-06-15
Project End
2012-05-31
Budget Start
2008-06-15
Budget End
2009-05-31
Support Year
1
Fiscal Year
2008
Total Cost
$433,329
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Higgins, Sarah J; De Ceunynck, Karen; Kellum, John A et al. (2018) Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest 128:1471-1484
Massey, Michael J; Hou, Peter C; Filbin, Michael et al. (2018) Microcirculatory perfusion disturbances in septic shock: results from the ProCESS trial. Crit Care 22:308
Fabian-Jessing, Bjorn K; Massey, Michael J; Filbin, Michael R et al. (2018) In vivo quantification of rolling and adhered leukocytes in human sepsis. Crit Care 22:240
Hou, Peter C; Filbin, Michael R; Wang, Henry et al. (2017) Endothelial Permeability and Hemostasis in Septic Shock: Results From the ProCESS Trial. Chest 152:22-31
Schuetz, Philipp; Birkhahn, Robert; Sherwin, Robert et al. (2017) Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med 45:781-789
Puskarich, Michael A; Shapiro, Nathan I; Massey, Michael J et al. (2016) Lactate Clearance in Septic Shock Is Not a Surrogate for Improved Microcirculatory Flow. Acad Emerg Med 23:690-3
Massey, Michael J; Shapiro, Nathan I (2016) A guide to human in vivo microcirculatory flow image analysis. Crit Care 20:35
Shapiro, N I; Angus, D C (2014) A review of therapeutic attempts to recruit the microcirculation in patients with sepsis. Minerva Anestesiol 80:225-35
Ginde, Adit A; Blatchford, Patrick J; Trzeciak, Stephen et al. (2014) Age-related differences in biomarkers of acute inflammation during hospitalization for sepsis. Shock 42:99-107
Kennedy, Maura; Enander, Richard A; Tadiri, Sarah P et al. (2014) Delirium risk prediction, healthcare use and mortality of elderly adults in the emergency department. J Am Geriatr Soc 62:462-9

Showing the most recent 10 out of 39 publications